Delta-like ligand 3 in small cell lung cancer: Potential mechanism and treatment progress

Weichang Yang; Wenjun Wang; Zhouhua Li; Juan Wu; Xiaotian Huang; Jinbo Li; Xinyi Zhang; Xiaoqun Ye

doi:10.1016/j.critrevonc.2023.104136

Delta-like ligand 3 in small cell lung cancer: Potential mechanism and treatment progress

Crit Rev Oncol Hematol. 2023 Nov:191:104136. doi: 10.1016/j.critrevonc.2023.104136. Epub 2023 Sep 15.

Authors

Weichang Yang¹, Wenjun Wang¹, Zhouhua Li¹, Juan Wu¹, Xiaotian Huang¹, Jinbo Li¹, Xinyi Zhang¹, Xiaoqun Ye²

Affiliations

¹ Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
² Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. Electronic address: 511201663@qq.com.

PMID: 37716517
DOI: 10.1016/j.critrevonc.2023.104136

Abstract

Small cell lung cancer (SCLC) is one of a pathological type of lung cancer, and it is characterized by invasiveness, high malignancy and refractoriness. The mortality rate of SCLC is significantly higher than other types of lung cancer, and the treatment options for SCLC patients are limited. Delta-like ligand 3 (DLL3) is a Notch signaling ligand that plays a role in regulating the proliferation, development and metastasis of SCLC cells. Mnay studies have shown that DLL3 is overexpressed on the surface of SCLC cells, suggesting that DLL3 is a potential target for SCLC patients. A series of drug trials targeting DLL3 are underway. The Phase III clinical trials of Rova-T, a drug targeting DLL3, have not yielded the expected results. However, other drugs that target DLL3, such as AMG119, AMG757 and DLL3-targeted NIR-PIT, bring new ideas for SCLC treatment. Overall, DLL3 remains a valuable target for SCLC.

Keywords: Delta-like ligand 3; Mechanism; Notch signal; Small cell lung cancer; Treatment.

Publication types

Review